[Blood coagulation disorders observed in arteriosclerosis obliterans].
Activated platelet function indicated by beta-TG and PF4 is observed in the patients from arteriosclerosis obliterans (ASO) with severe disturbance of peripheral circulation. Increase in FpA, TAT, FDP and PIC suggest that blood coagulation and fibrinolysis are accelerated. Fibrinolysis might be activated in response to thrombus formation in screlotic peripheral artery. It is suggested that antiplatelet and/or anticoagulation therapy is acceptable for ASO with disorders of blood coagulation and fibrinolysis. Adequate antithrombotic therapy is necessary not only to treat ASO but also to prevent progression of arterioscrelosis. It is important to recognize harmful influence of antithrombotic therapy (antiplatelet, anticoagulation or thrombolysis) on blood coagulation and fibrinolysis, on the patient being canditate for vascular surgery.
Ishimaru
S
S
Department of Surgery II, Tokyo Medical College, Japan.
D001162:Arteriosclerosis Obliterans / Q000097:blood / Q000150:complications*; D001778:Blood Coagulation Disorders / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D000075202:Contraindications; D005342:Fibrinolysis; D006801:Humans; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010978:Platelet Factor 4 / Q000378:metabolism; D001620:beta-Thromboglobulin / Q000378:metabolism
D010975:Platelet Aggregation Inhibitors; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4